Pharmicell Co., Ltd. (KRX:005690)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,180
+830 (5.08%)
Last updated: Apr 9, 2026, 12:46 PM KST
Market Cap981.07B +29.4%
Revenue (ttm)23.94B -3.6%
Net Income-26.78B
EPS-613.75
Shares Out60.00M
PE Ration/a
Forward PEn/a
Dividend50.00 (0.33%)
Ex-Dividend DateDec 29, 2025
Volume1,523,524
Average Volume686,389
Open16,000
Previous Close16,350
Day's Range15,980 - 17,440
52-Week Range8,150 - 20,800
Beta0.58
RSI55.33
Earnings Daten/a

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1968
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 005690
Full Company Profile

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.

Financial Statements